IRVINE, Calif.--(BUSINESS WIRE)--Visiogen, Inc. of Irvine, California, announced it has received approval from the U.S. Food & Drug Administration (FDA) for full expansion of its Phase III U.S. clinical trial for its Synchrony® dual optic accommodating intraocular lens. Already approved for use throughout the European Union, the Synchrony system is being studied in a multi-center trial in the U.S. to evaluate safety and effectiveness and the potential for near and intermediate vision without the use of spectacles in patients post cataract surgery.
